Does Rallies show Form 4 insider transactions for QNCX?

Yes. Rallies tracks QNCX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is QNCX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for QNCX. It does not provide personalized investment advice.

QNCX (Quince Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Quince Therapeutics, Inc. Common Stock (QNCX) is a publicly traded Healthcare sector company. As of May 21, 2026, QNCX trades at $1.04 with a market cap of $16.22M and a P/E ratio of -0.64. QNCX moved +0.00% today. Year to date, QNCX is -96.22%; over the trailing twelve months it is -89.41%. Its 52-week range spans $0.79 to $45.50. Rallies surfaces QNCX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading QNCX stock inside the company?

Recent QNCX insider activity includes Benatti Luca sold 50.00K, Thye Dirk bought 77.00K, Thye Dirk bought 77.50K, Hannah Brendan bought 2.28K, and Hannah Brendan bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

QNCX Key Metrics

Key financial metrics for QNCX
Metric	Value
Price	$1.04
Market Cap	$16.22M
P/E Ratio	-0.64
EPS	$-1.68
Dividend Yield	0.00%
52-Week High	$45.50
52-Week Low	$0.79
Volume	97.21K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-80.77M
Gross Margin	0.00%

Recent QNCX Insider Trades

Benatti Luca sold 50.00K (~$173.50K) on Dec 26, 2025.
Thye Dirk bought 77.00K (~$53.90K) on Aug 30, 2024.
Thye Dirk bought 77.50K (~$53.47K) on Aug 29, 2024.
Hannah Brendan bought 2.28K (~$1.39K) on Aug 21, 2024.
Hannah Brendan bought 5.00K (~$3.10K) on Aug 21, 2024.

Latest QNCX News

Quince Therapeutics surges 53% after hiring LifeSci Capital for reverse merger review — Feb 13, 2026
Quince Therapeutics Engages LifeSci Capital, Shares Soar 54% in Premarket — Feb 10, 2026
Analysts Set $8.00 Average Price Target with Moderate Buy Rating for Quince Therapeutics — Jan 12, 2026
Analysts Set $8.00 Price Objective as Quince Therapeutics Reports $0.25 Q3 EPS Loss — Jan 12, 2026
Quince Therapeutics Sets Phase 3 NEAT Readout Mid-Q1 2026 Targeting $1B Orphan Market — Jan 12, 2026

QNCX Analyst Consensus

QNCX analyst coverage data. Average price target: $0.00.

Common questions about QNCX

Who is trading QNCX stock inside the company?: Recent QNCX insider activity includes Benatti Luca sold 50.00K, Thye Dirk bought 77.00K, Thye Dirk bought 77.50K, Hannah Brendan bought 2.28K, and Hannah Brendan bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for QNCX?: Yes. Rallies tracks QNCX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is QNCX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for QNCX. It does not provide personalized investment advice.